Secukinumab-induced Oral Lichen Planus: A Report of Case and Review of Literature
Recent years, we are witnessing a more frequent use of biological agent treatments. Secukinumab (SEC) has been used successfully in the management of psoriasis, psoriatic arthritis, and ankylosing spondylitis. However, the cases of SEC-related lichen planus (LP) are rarely encountered in the literat...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Yayinevi
2021-08-01
|
| Series: | İstanbul Medical Journal |
| Subjects: | |
| Online Access: |
http://istanbulmedicaljournal.org/archives/archive-detail/article-preview/secukinumab-induced-oral-lichen-planus-a-report-of/48473
|
| Summary: | Recent years, we are witnessing a more frequent use of biological agent treatments. Secukinumab (SEC) has been used successfully in the management of psoriasis, psoriatic arthritis, and ankylosing spondylitis. However, the cases of SEC-related lichen planus (LP) are rarely encountered in the literature. Herein, this report presents a case of oral LP induced by SEC in a 33-year-old patient with psoriasis. In addition, this report aims to review the lichen reactions associated with SEC in the literature. In conclusion, LP cases attributable to SEC use are increasingly being observed in new reports. Clinicians who use SEC in their patients should be aware of this side effect and observe patients in terms of cutaneous-mucosal LP. With the introduction of new interleukin-17 (IL-17) inhibitors, the reporting of side effects is crucial for learning whether LP is class side effects or drug-specific side effects for clarifying pathogenesis. Dermatologists and rheumatologists should be aware of the very rare negative effect of IL-17 inhibitors. |
|---|---|
| ISSN: | 2619-9793 2148-094X |